Details for Patent: 8,648,077

Which drugs does patent 8,648,077 protect, and when does it expire?

Patent 8,648,077 protects CAPLYTA and is included in one NDA.

This patent has twenty-two patent family members in sixteen countries.

Summary for Patent: 8,648,077

Title:	4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrro- lo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Abstract:	The present invention relates to toluenesulfonic acid addition salt crystals of 4-((6bR,10aS)-3-Methyl-2,3,6b,9,10,10a-Hexahydro-1H-Pyrido[3',4':4,5]Pyrr- olo[1,2,3-De]Quinoxalin-8(7H)-yl)-1-(4-Fluorophenyl)-1-Butanone, the method of making and using such crystals.
Inventor(s):	Tomesch; John (New York, NY), Wennogle; Lawrence P. (New York, NY)
Assignee:	Intra-Cellular Therapies, Inc. (New York, NY)
Application Number:	12/922,056
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,648,077
Patent Claim Types: see list of patent claims	Composition; Compound; Process;

Drugs Protected by US Patent 8,648,077

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No			Y	Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No			Y	Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 8,648,077

PCT Information
PCT Filed	March 12, 2009	PCT Application Number:	PCT/US2009/001608
PCT Publication Date:	September 17, 2009	PCT Publication Number:	WO2009/114181

International Family Members for US Patent 8,648,077

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009223701
Canada	2716730
China	102046175
China	105237536